Bio Medica Laboratories Ltd. IPO

Our Company is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. We manufacture generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and ... veterinary needs. Our products address a wide range of medical needs and preferences. Our Company operates on a B2B business model through contract manufacturing and does not deal directly with the end users. Our company manufacture formulations for various companies according to their specific requirements and specifications for the type of formulation needed. Additionally, we enter into agreements with them, allowing their name and address to be displayed on the packaging as "Technical Collaborator" or “marketed by” alongside our Company’s name as the manufacturer. Our Company holds Good Manufacturing Practices (GMP) certificate issued by Food & Drugs Administration, Madhya Pradesh, for complying with established GMP standards and guidelines. Our company maintain stringent quality control standards throughout the entire manufacturing process. This ensures that our products consistently meet relevant quality standards before they reach the market. We also possess a Good Laboratory Practices (GLP) certificate issued by the Food & Drugs Administration, Madhya Pradesh, demonstrating our commitment in maintaining standards of quality and compliance in laboratory operations. Our in-house laboratory is equipped with various instruments, such as HPLC (HighPerformance Liquid Chromatography), GC (Gas Chromatography), UV-Vis (Ultraviolet-Visible Spectrophotometer), polarimeter, and other advanced equipments and instruments. This comprehensive array of tools enables us to conduct a wide range of tests and analyses efficiently and accurately. Read more

India’s pharmaceutical industry is one of the most significant contributors to the national economy and a key player in the global healthcare landscape. The country ranks third globally in pharmaceutical production by volume and 14th by value and is widely recognized as the “Pharmacy ... of the World” owing to its large-scale production and export of affordable, high- quality generic medicines and vaccines. India is the largest provider of generic drugs globally, accounting for approximately 20% of the global supply by volume and contributes over 60% of the global vaccine demand. As of 2024, India is home to over 3,000 pharmaceutical companies and more than 10,000 manufacturing facilities, including the highest number of USFDA-compliant plants outside the United States. This has positioned the country as a critical part of the global pharmaceutical supply chain, especially for regulated markets such as the United States, European Union, and Japan. The Indian pharmaceutical sector is evolving from a volume-driven industry to a value-based, innovation-led sector. There is a rising focus on complex generics, specialty drugs, biosimilars, and novel drug delivery systems, particularly in therapeutic areas such as oncology, cardiology, anti-diabetics, and central nervous system (CNS) disorders. Increasing investments in research and development (R&D), combined with strategic global partnerships and acquisitions, are enabling Indian pharmaceutical companies to enter higher-margin and technologically intensive product segments. Domestically, the Indian pharmaceutical market is witnessing robust growth, driven by rising healthcare awareness, increasing per capita income, expanding health insurance coverage, and improving access to healthcare facilities. Government initiatives such as Ayushman Bharat (PM-JAY), Jan Aushadhi Scheme, and the Production-Linked Incentive (PLI) Scheme for Pharmaceuticals are aimed at improving affordability and accessibility of medicines while enhancing domestic manufacturing competitiveness. Furthermore, India has emerged as a hub for Contract Research and Manufacturing Services (CRAMS) and clinical trial services, offering cost efficiencies, regulatory expertise, and skilled talent to global pharmaceutical and biotech companies. This has expanded India’s presence across the global pharmaceutical value chain, beyond generics manufacturing. The Indian pharmaceutical industry is expected to continue its growth trajectory, supported by strong export demand, policy support, expanding therapeutic coverage, and a gradual transition to high-value product portfolios. With continued focus on affordability, accessibility, and innovation, India is well-positioned to play a leading role in advancing global health outcomes in the coming decade Read more